Month: February 2023
-
ONL Therapeutics to Present at the XXVth Biennial Meeting of the International Society for Eye Research
ONL Therapeutics to Present at the XXVth Biennial Meeting of the International Society for Eye Research Oral presentation will review the scientific rationale for Fas receptor inhibition, a unique mechanism-of-action, in the treatment of patients with progressing open-angle glaucoma (OAG) ANN ARBOR, MI – February 13, 2023 ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel…
-
ONL Therapeutics to Present at 2023 BIO CEO & Investor Conference
ONL Therapeutics to Present at 2023 BIO CEO & Investor Conference ANN ARBOR, MI – February 2, 2023 ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, announced today that David Esposito, chief executive officer, will present a corporate update at the BIO CEO & Investor Conference…
-
ONL Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for ONL1204 Ophthalmic Solution
ONL Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for ONL1204 Ophthalmic Solution First-in-class small molecule Fas inhibitor with unique mechanism of action is designed to provide neuroprotection for retinal cells ANN ARBOR, MI – February 1, 2023 ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with…